文献

J-GLOBAL ID：201702225339432027   整理番号：17A0363006

調整された免疫原HIV中和抗体への直接的親和性成熟【Powered by NICT】

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

著者 (76件)： Briney Bryan (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Briney Bryan (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Briney Bryan (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sok Devin (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sok Devin (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sok Devin (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jardine Joseph G. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jardine Joseph G. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jardine Joseph G. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kulp Daniel W. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kulp Daniel W. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kulp Daniel W. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Skog Patrick (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Menis Sergey (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Menis Sergey (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Menis Sergey (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jacak Ronald (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kalyuzhniy Oleksandr (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kalyuzhniy Oleksandr (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kalyuzhniy Oleksandr (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  de Val Natalia (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  de Val Natalia (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  de Val Natalia (Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sesterhenn Fabian (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sesterhenn Fabian (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sesterhenn Fabian (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Le Khoa M. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Le Khoa M. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Le Khoa M. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ramos Alejandra (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ramos Alejandra (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ramos Alejandra (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jones Meaghan (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jones Meaghan (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Jones Meaghan (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Saye-Francisco Karen L. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Saye-Francisco Karen L. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Saye-Francisco Karen L. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Blane Tanya R. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Spencer Skye (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Spencer Skye (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Spencer Skye (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Georgeson Erik (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Georgeson Erik (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Georgeson Erik (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Hu Xiaozhen (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Hu Xiaozhen (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Hu Xiaozhen (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ozorowski Gabriel (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ozorowski Gabriel (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ozorowski Gabriel (Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Adachi Yumiko (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Adachi Yumiko (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Adachi Yumiko (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kubitz Michael (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kubitz Michael (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Kubitz Michael (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sarkar Anita (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sarkar Anita (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Sarkar Anita (Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Wilson Ian A. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Wilson Ian A. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Wilson Ian A. (Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Wilson Ian A. (Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ward Andrew B. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ward Andrew B. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Ward Andrew B. (Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Nemazee David (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Burton Dennis R. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Burton Dennis R. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Burton Dennis R. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Burton Dennis R. (Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02129, USA) ,  Schief William R. (Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Schief William R. (IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Schief William R. (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA) ,  Schief William R. (Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02129, USA)
資料名： Cell (Cambridge, Mass.)  (Cell (Cambridge, Mass.))
巻： 166  号： 6  ページ： 1459-1470.e11  発行年： 2016年 
JST資料番号： A0707B  ISSN： 0092-8674  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 広域中和抗体(bnAbs)の誘導は,HIVワクチン開発の主要な目標である。工学プライミング免疫原により標的化されたそれらの前駆体B細胞はヒトの中では比較的一般的なためVRC01クラスbnAbs重要であるワクチン。プライミング免疫原は,動物モデルにおいて,bnAb応答を開始する能力を実証したが,bnAbの発生に対する再現率と成熟は示されていない。ここでは,以前にプライムVRC01クラス前駆体の遺伝的および機能的成熟を誘導するために設計されたブースティング免疫原の開発を報告する。発現する生殖細胞系VRC01重鎖トランスジェニックマウスモデルのブースティング広い中和に近い分離株(N276A)と,完全に自然HIVの弱い中和を生成した。機能的および遺伝的特性はブーストmAbは部分的に成熟VRC01クラス抗体と一致し,成熟VRC01クラスbnAbsする成熟軌道上にあることを示した。結果は還元主義か逐次免疫はHIV bnAb応答の成熟を誘導できることを示した。Copyright 2017 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： ターゲティング ,  *抗体 ,  生殖細胞 ,  前駆体 ,  重鎖 ,  ヒト ,  *HIV【ウイルス】 ,  ワクチン ,  *中和抗体
準シソーラス用語： ブースティング ,  再現率 ,  動物モデル ,  AIDSワクチン ,  *親和性成熟 ,  *免疫原 , 【Automatic Indexing@JST】

分類 (1件)： 免疫反応一般  (ED03010T)

タイトルに関連する用語 (4件)： 免疫原 ,  HIV ,  中和抗体 ,  親和性成熟